FDA Approves Freeze-Dried Plasma for Military and Civilian Use
What happened
The FDA granted a general allowance for the use of freeze-dried plasma in both military and civilian sectors. This decision supports the RAPIID program, a $73 million initiative launched by the Defense Advanced Research Projects Agency to create shelf-stable synthetic blood alternatives. The program aims to deploy dried blood products by 2029.
From newsroomamerica.com
Why it matters
The initiative addresses a chronic blood shortage, which the American College of Surgeons estimates causes about 10,000 preventable deaths each year in the United States. The RAPIID program seeks to overcome the limitation that whole blood only lasts 35 days when refrigerated.
From newsroomamerica.com
Who's involved
- FDARegulatory agency that granted the general allowance for freeze-dried plasma.
- Defense Advanced Research Projects AgencyAgency running the $73 million RAPIID program to develop synthetic blood alternatives.
- Robert MurrayProgram manager employed by the Defense Advanced Research Projects Agency.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Defense Advanced Research Projects AgencySpeculative
The Defense Advanced Research Projects Agency might see increased investment in the RAPIID program due to the regulatory validation.
- Lockheed MartinSpeculative
Lockheed Martin might see increased contracts related to defense technology development informed by DARPA research.
- United States of AmericaSpeculative
The United States of America might see reduced costs associated with blood shortages in trauma care.
Keep exploring
The entities involved
- FDA
-
Defense Advanced Research Projects Agency
agency of the U.S. Department of Defense responsible for the development of new technologies